Iveric bio announces findings from exploratory analyses of data for ACP

Iveric bio announced new findings from exploratory analyses of data for avacincaptad pegol, or ACP, which were presented today at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology, in New Orleans. A post-hoc analysis from the GATHER1 and GATHER2 pivotal Phase 3 clinical trials showed, for the first time in an interventional study in GA, a relationship between GA growth and worsening vision loss. In this combined analysis, greater vision loss was correlated with increased GA growth. See accompanying graph. As previously announced, the post-hoc analysis of GATHER1 and GATHER2 combined data signaled a 56% risk reduction in the rate of persistent vision loss in GA patients receiving ACP 2 mg compared to sham over the first 12 months of treatment. Persistent vision loss was defined as a loss of greater than or equal to15 letters in Best Corrected Visual Acuity from baseline measured at any two consecutive visits up to month 12. Multiple sensitivity analyses were conducted to evaluate this finding, including 10- and 20-letter loss at two consecutive visits up to month 12, and results were consistent.